Back to School: How biopharma can reboot drug development. Access exclusive analysis here

A matter of design

At first glance, the design of Genentech Inc.'s Phase II trial of Avastin bevacizumab vs. Avastin plus Camptosar irinotecan for recurrent glioblastoma multiforme seems a bit odd, as it is more usual to compare an untested agent versus the new agent plus standard care.

In this case, however, neither

Read the full 492 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers